Iron Dextran

Summary

Iron Dextran (CHEMBL1201544) is a phase-3 clinical-stage unknown; indicated across 4 conditions including iron deficiency anemia and anemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201544
Name	Iron Dextran
Type	Unknown
Max phase	3

Also known as: Armidexan, Cosmofer, Ferrum, Ferran 100, Imferon, Iron dextran, Nonemic, IRON DEXTRAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
iron deficiency anemia	4	MONDO:0001356	HP:0001891
anemia	4	MONDO:0002280	EFO:0004272

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	3
PHASE2	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00593619	PHASE4	SUSPENDED	Trial Comparing the Safety of Two Different Intravenous Iron Formulations
NCT03438227	PHASE4	COMPLETED	Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
NCT05047211	PHASE4	COMPLETED	Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
NCT00704028	PHASE3	COMPLETED	Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
NCT03212781	PHASE3	COMPLETED	Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women
NCT01290315	PHASE2	COMPLETED	Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
NCT05167734	PHASE2	COMPLETED	Practical Anemia Bundle for SusTained Blood Recovery
NCT05960227	PHASE2	COMPLETED	Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).